Dietary intake of trans fatty acids and breast cancer risk in 9 European countries.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
30 03 2021
Historique:
received: 15 10 2020
accepted: 25 02 2021
entrez: 30 3 2021
pubmed: 31 3 2021
medline: 16 10 2021
Statut: epublish

Résumé

Trans fatty acids (TFAs) have been hypothesised to influence breast cancer risk. However, relatively few prospective studies have examined this relationship, and well-powered analyses according to hormone receptor-defined molecular subtypes, menopausal status, and body size have rarely been conducted. In the European Prospective Investigation into Cancer and Nutrition (EPIC), we investigated the associations between dietary intakes of TFAs (industrial trans fatty acids [ITFAs] and ruminant trans fatty acids [RTFAs]) and breast cancer risk among 318,607 women. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusted for other breast cancer risk factors. After a median follow-up of 8.1 years, 13,241 breast cancer cases occurred. In the multivariable-adjusted model, higher total ITFA intake was associated with elevated breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). A similar positive association was found between intake of elaidic acid, the predominant ITFA, and breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). Intake of total RTFAs was also associated with higher breast cancer risk (HR for highest vs lowest quintile, 1.09, 95% CI 1.01-1.17; P trend = 0.015). For individual RTFAs, we found positive associations with breast cancer risk for dietary intakes of two strongly correlated fatty acids (Spearman correlation r = 0.77), conjugated linoleic acid (HR for highest vs lowest quintile, 1.11, 95% CI 1.03-1.20; P trend = 0.001) and palmitelaidic acid (HR for highest vs lowest quintile, 1.08, 95% CI 1.01-1.16; P trend = 0.028). Similar associations were found for total ITFAs and RTFAs with breast cancer risk according to menopausal status, body mass index, and breast cancer subtypes. These results support the hypothesis that higher dietary intakes of ITFAs, in particular elaidic acid, are associated with elevated breast cancer risk. Due to the high correlation between conjugated linoleic acid and palmitelaidic acid, we were unable to disentangle the positive associations found for these fatty acids with breast cancer risk. Further mechanistic studies are needed to identify biological pathways that may underlie these associations.

Sections du résumé

BACKGROUND
Trans fatty acids (TFAs) have been hypothesised to influence breast cancer risk. However, relatively few prospective studies have examined this relationship, and well-powered analyses according to hormone receptor-defined molecular subtypes, menopausal status, and body size have rarely been conducted.
METHODS
In the European Prospective Investigation into Cancer and Nutrition (EPIC), we investigated the associations between dietary intakes of TFAs (industrial trans fatty acids [ITFAs] and ruminant trans fatty acids [RTFAs]) and breast cancer risk among 318,607 women. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusted for other breast cancer risk factors.
RESULTS
After a median follow-up of 8.1 years, 13,241 breast cancer cases occurred. In the multivariable-adjusted model, higher total ITFA intake was associated with elevated breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). A similar positive association was found between intake of elaidic acid, the predominant ITFA, and breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). Intake of total RTFAs was also associated with higher breast cancer risk (HR for highest vs lowest quintile, 1.09, 95% CI 1.01-1.17; P trend = 0.015). For individual RTFAs, we found positive associations with breast cancer risk for dietary intakes of two strongly correlated fatty acids (Spearman correlation r = 0.77), conjugated linoleic acid (HR for highest vs lowest quintile, 1.11, 95% CI 1.03-1.20; P trend = 0.001) and palmitelaidic acid (HR for highest vs lowest quintile, 1.08, 95% CI 1.01-1.16; P trend = 0.028). Similar associations were found for total ITFAs and RTFAs with breast cancer risk according to menopausal status, body mass index, and breast cancer subtypes.
CONCLUSIONS
These results support the hypothesis that higher dietary intakes of ITFAs, in particular elaidic acid, are associated with elevated breast cancer risk. Due to the high correlation between conjugated linoleic acid and palmitelaidic acid, we were unable to disentangle the positive associations found for these fatty acids with breast cancer risk. Further mechanistic studies are needed to identify biological pathways that may underlie these associations.

Identifiants

pubmed: 33781249
doi: 10.1186/s12916-021-01952-3
pii: 10.1186/s12916-021-01952-3
pmc: PMC8008592
doi:

Substances chimiques

Trans Fatty Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Références

BMJ Open. 2012 Sep 17;2(5):
pubmed: 22986123
Am J Epidemiol. 2008 Jun 1;167(11):1312-20
pubmed: 18390841
Cancer Causes Control. 2016 Jun;27(6):759-73
pubmed: 27146840
Breast Cancer Res Treat. 2014 May;145(1):255-65
pubmed: 24715379
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Cancer Res. 1997 Sep 15;57(18):3979-88
pubmed: 9307282
J Nutr. 2007 Dec;137(12):2599-607
pubmed: 18029471
Int J Cancer. 2018 Mar 15;142(6):1116-1129
pubmed: 29071721
Cancer Lett. 1997 Jun 24;116(2):121-30
pubmed: 9215854
Nutr Cancer. 2012;64(8):1131-42
pubmed: 23137008
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1439-49
pubmed: 26224798
Nutrients. 2020 Sep 23;12(10):
pubmed: 32977480
Ann Oncol. 2017 Nov 1;28(11):2836-2842
pubmed: 28950350
Am J Clin Nutr. 2003 Mar;77(3):532-43
pubmed: 12600840
BMC Cancer. 2008 Jul 24;8:208
pubmed: 18652667
Cancer Res. 1994 Mar 1;54(5):1212-5
pubmed: 8118808
Eur J Clin Nutr. 2009 May;63 Suppl 2:S5-21
pubmed: 19424218
Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):261-5
pubmed: 11895875
Atheroscler Suppl. 2006 May;7(2):1-4
pubmed: 16713396
Atheroscler Suppl. 2006 May;7(2):47-52
pubmed: 16713385
Eur J Clin Nutr. 2007 Sep;61(9):1037-56
pubmed: 17375121
Curr Atheroscler Rep. 2009 Nov;11(6):423-33
pubmed: 19852883
Nutr Cancer. 2003;45(2):190-4
pubmed: 12881013
Food Chem. 2016 Feb 15;193:134-40
pubmed: 26433299
Am J Clin Nutr. 2009 Sep;90(3):556-60
pubmed: 19491389
Am J Clin Nutr. 2002 Oct;76(4):873-82
pubmed: 12324303
J Natl Cancer Inst. 2014 Apr 09;106(5):
pubmed: 24718872
Lipids. 2014 May;49(5):403-13
pubmed: 24481861
BMJ. 2013 Jun 27;346:f3706
pubmed: 23814120
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nutr Res Rev. 2008 Dec;21(2):174-88
pubmed: 19087370
Am J Epidemiol. 1992 Jun 1;135(11):1301-9
pubmed: 1626547
Int J Epidemiol. 2019 Jun 1;48(3):795-806
pubmed: 30277539
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Br J Cancer. 2003 Nov 3;89(9):1672-85
pubmed: 14583769
Lancet. 2018 May 19;391(10134):1978-1980
pubmed: 29773233
Clin Nutr. 2020 Mar;39(3):755-764
pubmed: 30954361

Auteurs

Michèle Matta (M)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Inge Huybrechts (I)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Carine Biessy (C)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Corinne Casagrande (C)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Sahar Yammine (S)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Agnès Fournier (A)

CESP "Health Across Generations", INSERM, Univ Paris-Sud, UVSQ, Univ Paris-Saclay, Villejuif, France.
Gustave Roussy, Villejuif, France.

Karina Standahl Olsen (KS)

Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Marco Lukic (M)

Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Inger Torhild Gram (IT)

Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Eva Ardanaz (E)

Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Maria-José Sánchez (MJ)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.

Laure Dossus (L)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Renée T Fortner (RT)

Division of Cancer Epidemiology, German Cancer Research Centre (DFKZ), Heidelberg, Germany.

Bernard Srour (B)

Division of Cancer Epidemiology, German Cancer Research Centre (DFKZ), Heidelberg, Germany.

Franziska Jannasch (F)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
NutriAct - Competence Cluster Nutrition Research Berlin-Potsdam, Nuthetal, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.

Antonio Agudo (A)

Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, 08908, Barcelona, Spain.

Sandra Colorado-Yohar (S)

Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

J Ramón Quirós (JR)

Public Health Directorate, Asturias, Spain.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7), Ragusa, Italy.

Salvatore Panico (S)

Dipartimento Di Medicina Clinica e Chirurgia, Federici II University, Naples, Italy.

Giovanna Masala (G)

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Valeria Pala (V)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, di Milano Via Venezian, 1, 20133, Milan, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Via Santena 7, 10126, Turin, Italy.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
Department of Public Health, Copenhagen University, Copenhagen, Denmark.

Anja Olsen (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
Department of Public Health, Aarhus University, Aarhus, Denmark.

Christina C Dahm (CC)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Ann H Rosendahl (AH)

Clinical Sciences Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.

Signe Borgquist (S)

Clinical Sciences Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Department of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.

Maria Wennberg (M)

Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, Imperial College London, London, UK.

Dagfinn Aune (D)

Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
Department of Nutrition, Bjørknes University College, Oslo, Norway.
Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital Ullevål, Oslo, Norway.

Julie Schmidt (J)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Elisabete Weiderpass (E)

Office of the Director, International Agency for Research on Cancer, Lyon, France.

Veronique Chajes (V)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Marc J Gunter (MJ)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France.

Neil Murphy (N)

Nutrition and Metabolism Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372, Lyon Cedex 08, France. murphyn@iarc.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH